Gut bacteria and liver cancer trial
Part of Cancer, Digestive system clinical trials.
This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have liver cancer that cannot be removed by surgery and is at stage B or C
- Your cancer progressed after treatment with TKIs and immunotherapy
- You cannot have local ablation or chemoembolization
- Your liver function is good (Child-Pugh Grade A)
- You have at least one tumor that can be measured on a scan
- You are able to do daily activities with little or no help (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a combination of targeted therapy (TKI) and immunotherapy (ICI) affects the gut bacteria in people with advanced liver cancer that cannot be surgically removed. It aims to see if changes in the microbiome can help predict treatment response.
This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.